Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment that could offer a new option for patients with limited therapeutic alternatives. The company’s Chief Medical Officer, Dr. Islam Mohamed, recently appeared on the IBN BioMedWire Podcast to discuss the company’s lead drug candidate, ONC010, and its planned first-in-human clinical program. The podcast appearance, announced in a press release, underscores the potential of ONC010 to address cancers that have lost the tumor suppressors PTEN or SHP-1.
ONC010 is designed to inhibit polynucleotide kinase phosphatase (PNKP), a DNA repair enzyme. By targeting PNKP, the drug aims to exploit a concept known as synthetic lethality. This approach is intended to limit the drug’s lethal effects to cancer cells that have lost PTEN or SHP-1, which are common genetic alterations in many cancers. In addition, ONC010 uses nanoparticle delivery intended to concentrate the drug within tumor tissue, potentially reducing systemic toxicity and enhancing efficacy.
During the podcast, Dr. Mohamed highlighted preclinical research conducted at the University of Alberta. In these studies, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings provide a strong rationale for moving ONC010 into human trials. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response.
The significance of this announcement lies in the potential of ONC010 to address a critical unmet need in oncology. Many cancers become resistant to existing therapies due to their ability to repair DNA damage. By targeting PNKP, Onco-Innovations hopes to overcome this resistance and provide a new treatment avenue for patients whose tumors have lost PTEN or SHP-1. If successful, ONC010 could become a first-in-class therapy for these genetically defined cancers.
Moreover, the nanoparticle delivery system could improve the therapeutic index of PNKP inhibition, making the treatment more tolerable and effective. This dual selectivity mechanism—synthetic lethality and tumor-targeted delivery—could set ONC010 apart from conventional chemotherapies and other targeted agents. The planned first-in-human clinical program will be a key milestone in determining whether these preclinical advantages translate into clinical benefits.
For investors and the biotech community, this development signals progress in a cutting-edge area of cancer research. The podcast and the accompanying press release (https://ibn.fm/XgpMR) provide insight into the company’s strategy and the scientific basis for ONC010. As Onco-Innovations moves toward clinical testing, the results will be closely watched by those interested in novel DNA damage response therapies. The company’s newsroom (https://ibn.fm/ONNVF) offers ongoing updates on its progress.
BioMedWire, the platform that hosted the podcast, is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, and social media distribution. For more information, visit https://www.BioMedWire.com.
